Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03823131
Title Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Francisco San Francisco California 94143 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field